<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350973</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-085/CCT-002</org_study_id>
    <secondary_id>JapicCTI-090937</secondary_id>
    <secondary_id>U1111-1120-7801</secondary_id>
    <secondary_id>JapicCTI-R140452</secondary_id>
    <nct_id>NCT01350973</nct_id>
  </id_info>
  <brief_title>Efficacy of TAK-085 in Participants With Hypertriglyceridemia</brief_title>
  <official_title>A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the efficacy and safety of TAK-085, once daily
      (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily
      (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085
      contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl
      docosahexaenoic acid (DHA-E)).

      This is a phase 3, double-blind, randomized study to evaluate the efficacy and safety of
      TAK-085 compared to EPA-E in participants with hypertriglyceridemia who are undergoing
      lifestyle modification.

      The study period is a total of 20 weeks, comprised of an 8- week screening period and 12
      weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Triglyceride Level at the Final Visit</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The percentage change between triglycerides collected at the end of study drug administration (the end of treatment period or discontinuation) relative to Baseline. Analysis of Covariance (ANCOVA) model was employed, using the Baseline triglyceride level as covariate and the treatment group as an independent variable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglyceride Level Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
    <description>The percentage change between triglycerides collected at each study visit relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C) Level Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
    <description>The percentage change between low-density lipoprotein cholesterol collected at each study visit relative to Baseline. Low-density lipoprotein cholesterol particles measured directly by nuclear magnetic resonance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
    <description>The percentage change between total cholesterol measured at each study visit relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C) Level Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
    <description>The percentage change between high-density lipoprotein cholesterol collected at each study visit relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol Level Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
    <description>The percentage change between non-high-density lipoprotein cholesterol collected at each study visit relative to Baseline. Non-high-density lipoprotein cholesterol calculated by subtracting high-density lipoprotein cholesterol from total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings After Study Drug Administration</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">611</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>TAK-085 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-085 4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA-E 1.8 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3-acid ethyl esters 90 (TAK-085)</intervention_name>
    <description>Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.</description>
    <arm_group_label>TAK-085 2 g</arm_group_label>
    <arm_group_label>TAK-085 4 g</arm_group_label>
    <other_name>LOVAZA</other_name>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic acid-ethyl (EPA-E)</intervention_name>
    <description>EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.</description>
    <arm_group_label>EPA-E 1.8 g</arm_group_label>
    <other_name>Atheropan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with values of fasting triglyceride level at Visit 2 (Week -4) and Visit
             3 (Week -2) are 150 mg/dL or higher and less than 750 mg/dL, and the difference
             between these 2 values is within 30% of the higher one.

          2. Participants with differences between 2 values of fasting Low density lipoprotein -
             cholesterol level measured at Visit 2 (Week -4) and Visit 3 (Week -2) are within 25%
             of the higher one.

        Exclusion Criteria:

          1. Participants who have coronary artery diseases (eg, confirmed myocardial infarction
             and angina pectoris) within 6 months prior to Visit 1 (Week -8) or participants with a
             history of revascularization.

          2. Participants who received aortic aneurysmectomy or is complicated with aortic aneurysm
             within 6 months prior to Visit 1 (Week -8).

          3. Participants who have a history or complication of a clinically significant
             hemorrhagic disease (eg, hemophilia, capillary fragility illness, digestive tract
             ulcer, urinary tract hemorrhage, hemoptysis, vitreous haemorrhage and so forth) within
             6 months prior to Visit 1 (Week -8).

          4. Participants who have been diagnosed with pancreatitis.

          5. Participants who have been diagnosed with lipoprotein lipase (LPL) deficiency,
             apolipoprotein C-II deficiency or type III familial hyperlipidemia.

          6. Participants with complication of Cushing's syndrome, uremia, systemic lupus
             erythematosus (SLE) or serum dysproteinemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Associate Professor, Clinical Cell Biology and Medicine</last_name>
    <role>Study Director</role>
    <affiliation>Graduate School of Medicine, Chiba University</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <results_first_submitted>June 1, 2016</results_first_submitted>
  <results_first_submitted_qc>July 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2016</results_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 69 investigational sites in Japan from 21 November 2009 to 28 December 2010.</recruitment_details>
      <pre_assignment_details>Participants with hypertriglyceridemia were randomized to receive omega-3-acid ethyl esters 90 (TAK-085) 2 g once daily or TAK-085 2 g twice daily or EPA-E 0.6 g three-times daily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-085 2 g</title>
          <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>TAK-085 4 g</title>
          <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>EPA-E 1.8 g</title>
          <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TAK-085 2 g</title>
          <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>TAK-085 4 g</title>
          <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>EPA-E 1.8 g</title>
          <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="206"/>
            <count group_id="B2" value="210"/>
            <count group_id="B3" value="195"/>
            <count group_id="B4" value="611"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="10.76"/>
                    <measurement group_id="B2" value="55.0" spread="10.50"/>
                    <measurement group_id="B3" value="55.6" spread="10.52"/>
                    <measurement group_id="B4" value="54.8" spread="10.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥20 - &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 - ≤74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopause Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;160 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥160 - &lt;170 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥170 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.5" spread="8.60"/>
                    <measurement group_id="B2" value="165.7" spread="8.64"/>
                    <measurement group_id="B3" value="166.0" spread="8.89"/>
                    <measurement group_id="B4" value="165.7" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight, Categorical</title>
          <description>The number of participants with available weight data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥60.0 - &lt;70.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥70.0 - &lt;80.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥80.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>The number of participants with available weight data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.04" spread="13.139"/>
                    <measurement group_id="B2" value="72.20" spread="12.435"/>
                    <measurement group_id="B3" value="72.90" spread="13.375"/>
                    <measurement group_id="B4" value="72.71" spread="12.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI), Categorical</title>
          <description>The number of participants with available BMI data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;25.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥25.0 - &lt;30.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>The number of participants with available BMI data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.55" spread="3.658"/>
                    <measurement group_id="B2" value="26.26" spread="3.846"/>
                    <measurement group_id="B3" value="26.34" spread="3.628"/>
                    <measurement group_id="B4" value="26.38" spread="3.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference, Categorical</title>
          <description>The number of participants with available waist circumference data are 205, 210 and 195 in each treatment arm, respectively.
Mean</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male &lt;85.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male ≥85.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female &lt;90.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female ≥90.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <description>The number of participants with available waist circumference data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.85" spread="8.901"/>
                    <measurement group_id="B2" value="91.24" spread="9.376"/>
                    <measurement group_id="B3" value="91.51" spread="9.232"/>
                    <measurement group_id="B4" value="91.53" spread="9.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease (CAD) Category</title>
          <description>CAD Patient Categories define the degree of risk of CAD according to Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. Categories are classified by the degree of risks in the patient [e.g, smoking, hypertension, excluding level of low density lipoprotein cholesterol (LDL-C)]. Category I=Low risk (best), Category II=Middle risk, Category III=High Risk and History of CAD.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Category I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of CAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus (Including Impaired Glucose Tolerance)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low High Density Lipoprotein - Cholesterol (HDL-C)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Administration of 3-hydroxy 3-methylglutaryl coenzyme A (HMGCoA) Reductase Inhibitor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides, Categorical</title>
          <description>The number of participants with available triglyceride data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;150 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥150 - &lt;300 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥300 - &lt;500 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥500 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>The number of participants with available triglyceride data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269.0" spread="77.52"/>
                    <measurement group_id="B2" value="277.5" spread="97.29"/>
                    <measurement group_id="B3" value="271.8" spread="91.53"/>
                    <measurement group_id="B4" value="272.8" spread="89.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein - Cholesterol (LDL-C), Categorical</title>
          <description>The number of participants with available LDL-C data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;140 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥140 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein - Cholesterol (LDL-C)</title>
          <description>The number of participants with available LDL-C data are 205, 210 and 195 in each treatment arm, respectively.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127.4" spread="29.08"/>
                    <measurement group_id="B2" value="125.7" spread="28.50"/>
                    <measurement group_id="B3" value="130.1" spread="30.54"/>
                    <measurement group_id="B4" value="127.7" spread="29.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Triglyceride Level at the Final Visit</title>
        <description>The percentage change between triglycerides collected at the end of study drug administration (the end of treatment period or discontinuation) relative to Baseline. Analysis of Covariance (ANCOVA) model was employed, using the Baseline triglyceride level as covariate and the treatment group as an independent variable.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set including all participants who were randomized and received at least one dose of the investigational product and with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglyceride Level at the Final Visit</title>
          <description>The percentage change between triglycerides collected at the end of study drug administration (the end of treatment period or discontinuation) relative to Baseline. Analysis of Covariance (ANCOVA) model was employed, using the Baseline triglyceride level as covariate and the treatment group as an independent variable.</description>
          <population>Full analysis set including all participants who were randomized and received at least one dose of the investigational product and with available data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.93" spread="1.6434" lower_limit="-14.1610" upper_limit="-7.7062"/>
                    <measurement group_id="O2" value="-22.65" spread="1.6238" lower_limit="-25.8436" upper_limit="-19.4655"/>
                    <measurement group_id="O3" value="-11.30" spread="1.6807" lower_limit="-14.6014" upper_limit="-7.9998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8760</p_value>
            <p_value_desc>An ANCOVA model was employed, using the baseline triglyceride level as covariate and the treatment group as an independent variable.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2491</ci_lower_limit>
            <ci_upper_limit>4.9830</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>An ANCOVA model was employed, using the baseline triglyceride level as covariate and the treatment group as an independent variable.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.9442</ci_lower_limit>
            <ci_upper_limit>-6.7637</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglyceride Level Over Time</title>
        <description>The percentage change between triglycerides collected at each study visit relative to Baseline.</description>
        <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglyceride Level Over Time</title>
          <description>The percentage change between triglycerides collected at each study visit relative to Baseline.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=203, 208, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.085" spread="26.4479"/>
                    <measurement group_id="O2" value="-26.939" spread="20.9540"/>
                    <measurement group_id="O3" value="-11.417" spread="27.8599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=199, 205, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.055" spread="23.5955"/>
                    <measurement group_id="O2" value="-22.501" spread="29.7039"/>
                    <measurement group_id="O3" value="-11.321" spread="29.6792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=198, 202, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.707" spread="25.9148"/>
                    <measurement group_id="O2" value="-23.436" spread="31.7008"/>
                    <measurement group_id="O3" value="-11.416" spread="28.4762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=198, 199, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.707" spread="27.6764"/>
                    <measurement group_id="O2" value="-22.606" spread="25.1665"/>
                    <measurement group_id="O3" value="-12.431" spread="31.0903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C) Level Over Time</title>
        <description>The percentage change between low-density lipoprotein cholesterol collected at each study visit relative to Baseline. Low-density lipoprotein cholesterol particles measured directly by nuclear magnetic resonance.</description>
        <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C) Level Over Time</title>
          <description>The percentage change between low-density lipoprotein cholesterol collected at each study visit relative to Baseline. Low-density lipoprotein cholesterol particles measured directly by nuclear magnetic resonance.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=203, 208, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.120" spread="16.0172"/>
                    <measurement group_id="O2" value="2.262" spread="15.5408"/>
                    <measurement group_id="O3" value="-3.409" spread="13.5003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=200, 205, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.846" spread="15.5473"/>
                    <measurement group_id="O2" value="-0.420" spread="17.7696"/>
                    <measurement group_id="O3" value="-3.008" spread="13.8462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=199, 202, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.055" spread="15.6128"/>
                    <measurement group_id="O2" value="-0.862" spread="18.0310"/>
                    <measurement group_id="O3" value="-4.297" spread="14.0827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=199, 200, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.639" spread="16.3582"/>
                    <measurement group_id="O2" value="-1.056" spread="18.2732"/>
                    <measurement group_id="O3" value="-3.393" spread="17.2972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol Over Time</title>
        <description>The percentage change between total cholesterol measured at each study visit relative to Baseline.</description>
        <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol Over Time</title>
          <description>The percentage change between total cholesterol measured at each study visit relative to Baseline.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=203, 208, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.841" spread="10.0601"/>
                    <measurement group_id="O2" value="-2.707" spread="9.0969"/>
                    <measurement group_id="O3" value="-3.152" spread="8.1026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=200, 205, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.996" spread="9.5190"/>
                    <measurement group_id="O2" value="-2.887" spread="9.7964"/>
                    <measurement group_id="O3" value="-3.097" spread="9.2770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=199, 202, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.054" spread="9.0927"/>
                    <measurement group_id="O2" value="-3.949" spread="10.5345"/>
                    <measurement group_id="O3" value="-4.355" spread="9.1420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=199, 200, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.649" spread="9.4133"/>
                    <measurement group_id="O2" value="-3.243" spread="10.6025"/>
                    <measurement group_id="O3" value="-3.880" spread="10.8594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C) Level Over Time</title>
        <description>The percentage change between high-density lipoprotein cholesterol collected at each study visit relative to Baseline.</description>
        <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C) Level Over Time</title>
          <description>The percentage change between high-density lipoprotein cholesterol collected at each study visit relative to Baseline.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=203, 208, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.990" spread="10.5365"/>
                    <measurement group_id="O2" value="4.075" spread="10.9735"/>
                    <measurement group_id="O3" value="0.934" spread="11.6203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=200, 205, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.547" spread="11.6333"/>
                    <measurement group_id="O2" value="3.936" spread="12.4198"/>
                    <measurement group_id="O3" value="1.826" spread="10.1747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=199, 202, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.258" spread="10.6907"/>
                    <measurement group_id="O2" value="4.219" spread="12.0895"/>
                    <measurement group_id="O3" value="1.860" spread="11.0573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=199, 200, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.685" spread="10.8647"/>
                    <measurement group_id="O2" value="4.564" spread="12.7497"/>
                    <measurement group_id="O3" value="1.741" spread="10.8185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol Level Over Time</title>
        <description>The percentage change between non-high-density lipoprotein cholesterol collected at each study visit relative to Baseline. Non-high-density lipoprotein cholesterol calculated by subtracting high-density lipoprotein cholesterol from total cholesterol.</description>
        <time_frame>Baseline and Weeks 4, 8, 10 and 12</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol Level Over Time</title>
          <description>The percentage change between non-high-density lipoprotein cholesterol collected at each study visit relative to Baseline. Non-high-density lipoprotein cholesterol calculated by subtracting high-density lipoprotein cholesterol from total cholesterol.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=203, 208, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.955" spread="12.7395"/>
                    <measurement group_id="O2" value="-4.634" spread="11.3386"/>
                    <measurement group_id="O3" value="-4.274" spread="10.8403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=200, 205, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.022" spread="11.2524"/>
                    <measurement group_id="O2" value="-4.931" spread="11.9003"/>
                    <measurement group_id="O3" value="-4.418" spread="11.5415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=199, 202, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.624" spread="11.2058"/>
                    <measurement group_id="O2" value="-6.190" spread="12.9755"/>
                    <measurement group_id="O3" value="-5.994" spread="11.1866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=199, 200, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.159" spread="11.5205"/>
                    <measurement group_id="O2" value="-5.384" spread="13.2602"/>
                    <measurement group_id="O3" value="-5.140" spread="14.3444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <time_frame>12 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs</title>
        <time_frame>12 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="10.81"/>
                    <measurement group_id="O2" value="0" spread="10.61"/>
                    <measurement group_id="O3" value="0" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</title>
        <time_frame>12 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings After Study Drug Administration</title>
        <time_frame>12 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings After Study Drug Administration</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collection of AEs commenced from the time that the subject was first administered investigational product (Week 0). Routine collection of AEs continued until the completion of study treatment (12 weeks of administration)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-085 2 g</title>
          <description>TAK-085 2 g, orally, once daily for up to 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>TAK-085 4 g</title>
          <description>TAK-085 2 g, orally, twice daily for up to 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>EPA-E 1.8 g</title>
          <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

